Bellus Health (NASDAQ: BLU) Investor Relations Program
Bellus Health is a clinical-stage biopharmaceutical company focused on developing a P2X3 antagonist to address refractory chronic cough and other hypersensitization disorders.
BACKGROUND
Bellus Health is a clinical-stage biopharmaceutical company focused on developing a P2X3 antagonist to address refractory chronic cough and other hypersensitization disorders. The Company’s lead candidate, BLU-5937, is a highly selective P2X3 antagonist currently being developed for the treatment of refractory chronic cough. LifeSci Advisors has been engaged to support Bellus Health with investor outreach and engagement.
ACTION PLAN
LifeSci performed the following activities which ultimately converted several investor meetings into orders and led to an upward valuation of the company:
- Developed corporate calendar and IR roadmap
- Raised visibility of company and generated interest amongst investors through virtual and in-person non-deal-roadshows and KOL events strategically positioned throughout the year
- Proactively arranged meetings for Bellus with new investors in USA and Europe
- Organized a Group High Net Worth/ Family Office event in Europe
- Organized multiple KOL Dinners attended by investors and sell-side analysts
- Marketed corporate news flow to investors including the successful completion of the End-of-Phase 2 meeting with the FDA
- Developed relationships with the sell-side resulting in an increased attendance at multiple investment banking conferences
RESULTS
Since February 2022, Bellus has met with over 60 investors. LifeSci arranged a total of 18 high net worth/family office meetings and 46 institutional meetings. In February 2022, the stock was trading at $5.56. By September 2022, the stock was trading at $10.75, resulting in a 93% return. Bellus successfully closed a $153M Public Offering of Common Shares in July 2022.